Profile data is unavailable for this security.
About the company
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. It is in the process of building its preclinical pipeline, which focuses primarily on immuno-oncology. Its pipeline includes IBIO-101, Endostatin E4, TROP-2 x CD3, MUC16, EGFRvIII, and CCR8. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
- Revenue in USD (TTM)50.00k
- Net income in USD-17.13m
- Incorporated2008
- Employees26.00
- LocationIbio Inc8800 HSC PkwyBRYAN 77807United StatesUSA
- Phone+1 (979) 446-0027
- Fax+1 (302) 636-5454
- Websitehttps://www.ibioinc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indaptus Therapeutics Inc | 0.00 | -14.98m | 21.09m | 7.00 | -- | 2.25 | -- | -- | -1.78 | -1.78 | 0.00 | 1.10 | 0.00 | -- | -- | 0.00 | -87.86 | -66.55 | -97.46 | -81.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.68 | -- | -- | -- |
| Jaguar Health Inc | 10.14m | -38.32m | 21.40m | 49.00 | -- | 1.54 | -- | 2.11 | -78.63 | -78.63 | 9.90 | 3.18 | 0.1806 | 0.2397 | 8.12 | 206,938.80 | -69.22 | -95.29 | -122.86 | -163.54 | 79.07 | 67.28 | -383.35 | -522.28 | 1.39 | -2.78 | 0.6919 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
| Cumberland Pharmaceuticals, Inc. | 38.83m | -8.42m | 21.43m | 91.00 | -- | 0.7778 | -- | 0.5519 | -0.596 | -0.596 | 2.72 | 1.94 | 0.4542 | 0.8812 | 3.08 | 426,654.70 | -9.83 | -7.03 | -14.07 | -9.52 | 83.54 | 79.95 | -21.65 | -17.64 | 1.21 | -37.10 | 0.3717 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
| Eom Pharmaceutical Holdings Inc | 0.00 | -4.93m | 21.52m | 3.00 | -- | -- | -- | -- | -0.0435 | -0.0435 | 0.00 | -0.0212 | -- | -- | -- | 0.00 | -- | -126.34 | -- | -171.37 | -- | -- | -- | -- | -- | -- | 7.41 | -- | -- | -- | -254.37 | -- | -- | -- |
| Apollomics Inc | 0.00 | -388.09m | 21.84m | -- | -- | 0.3229 | -- | -- | -4.34 | -4.34 | 0.00 | 0.6225 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,391.69 | 0.012 | -- | -- | -- | -154.03 | -- | -- | -- |
| Ibio Inc | 50.00k | -17.13m | 22.08m | 26.00 | -- | 0.877 | -- | 441.53 | -13.10 | -17.09 | 0.0262 | 2.92 | 0.0011 | -- | 0.0065 | 1,923.08 | -36.24 | -28.09 | -67.39 | -32.63 | -- | -- | -34,258.00 | -1,467.30 | -- | -- | 0.3666 | -- | -100.00 | -- | 0.9764 | -- | 42.90 | -- |
| Goldenwell Biotech Inc | 1.08k | -114.27k | 22.28m | -- | -- | 414.42 | -- | 20,625.00 | -0.0012 | -0.0012 | 0.00001 | 0.0005 | 0.0052 | 0.0035 | -- | -- | -54.62 | -- | -54.97 | -- | 43.52 | -- | -10,580.56 | -- | 20.18 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
| Gain Therapeutics Inc | 0.00 | -21.14m | 22.38m | 29.00 | -- | 2.59 | -- | -- | -1.53 | -1.53 | 0.00 | 0.479 | 0.00 | -- | -- | 0.00 | -117.80 | -- | -164.29 | -- | -- | -- | -- | -13,827.07 | -- | -- | 0.0555 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
| NanoViricides Inc | 0.00 | -9.51m | 22.45m | 7.00 | -- | 2.11 | -- | -- | -0.8115 | -0.8115 | 0.00 | 0.9017 | 0.00 | -- | -- | 0.00 | -63.30 | -43.54 | -65.85 | -46.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.94 | -- | -8.90 | -- |
| Zivo Bioscience Inc | 63.37k | -7.08m | 22.63m | 8.00 | -- | -- | -- | 357.07 | -3.83 | -3.83 | 0.0318 | -0.8133 | 0.0652 | -- | -- | 7,921.25 | -728.52 | -376.60 | -- | -- | 38.05 | -- | -11,176.47 | -96,315.32 | -- | -88.46 | -- | -- | -- | -- | 11.07 | -- | -- | -- |
| Minerva Neurosciences Inc | 0.00 | -31.60m | 23.29m | 9.00 | -- | -- | -- | -- | -4.48 | -4.48 | 0.00 | -5.23 | 0.00 | -- | -- | 0.00 | -61.90 | -49.89 | -65.32 | -52.39 | -- | -- | -- | -442.65 | -- | -- | -- | -- | -- | -- | 6.55 | -- | -- | -- |
| bioAffinity Technologies Inc | 4.94m | -8.37m | 23.32m | 75.00 | -- | 4.27 | -- | 4.72 | -0.9197 | -0.9197 | 0.5416 | 0.4687 | 0.5334 | 318.22 | 8.70 | 65,839.60 | -90.38 | -- | -104.93 | -- | 32.88 | -- | -169.42 | -- | 2.21 | -- | 0.1782 | -- | 52,660.42 | -- | 2.66 | -- | -- | -- |
| Medicine Man Technologies Inc | -100.00bn | -100.00bn | 23.36m | 729.00 | -- | 0.3126 | -- | -- | -- | -- | -- | 1.33 | -- | -- | -- | -- | -- | -8.33 | -- | -9.85 | -- | 45.57 | -- | -15.71 | 0.2457 | -- | 0.6059 | -- | 8.20 | 78.78 | -62.56 | -- | 200.89 | -- |
| TherapeuticsMD Inc | 1.20m | -6.20m | 23.41m | 1.00 | -- | 0.8167 | -- | 19.53 | -0.58 | -0.6955 | 0.1103 | 2.49 | 0.0236 | -- | 0.4556 | 1,199,000.00 | -12.19 | -53.35 | -16.34 | -111.61 | 73.89 | 86.67 | -516.93 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
| Singular Genomics Systems Inc | 2.49m | -96.21m | 23.71m | 255.00 | -- | 0.1513 | -- | 9.52 | -1.31 | -1.31 | 0.034 | 2.12 | 0.0091 | 0.233 | 32.98 | 9,764.71 | -35.33 | -- | -37.29 | -- | -41.49 | -- | -3,863.90 | -- | 9.54 | -- | 0.0614 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
Data as of Jun 15 2024. Currency figures normalised to Ibio Inc's reporting currency: US Dollar USD
35.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Adar1 Capital Management LLCas of 05 Apr 2024 | 789.29k | 9.15% |
| Opaleye Management, Inc.as of 01 Apr 2024 | 650.00k | 7.54% |
| Lynx1 Capital Management LPas of 31 Mar 2024 | 600.00k | 6.96% |
| Ikarian Capital LLCas of 31 Mar 2024 | 600.00k | 6.96% |
| Armistice Capital LLCas of 31 Mar 2024 | 350.88k | 4.07% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 15.88k | 0.18% |
| Sabby Management LLCas of 31 Mar 2024 | 14.00k | 0.16% |
| FNY Capital Management LPas of 31 Mar 2024 | 9.00k | 0.10% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 5.82k | 0.07% |
| Tower Research Capital LLCas of 31 Mar 2024 | 5.60k | 0.07% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
